Track Zylox-Tonbridge Medical Technology , Ltd.'s EBIT ($370M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Jun 30, 2026
Trailing 12 months ending Jun 30, 2026
As of the most recent data (June 2026), 2190.HK shows a EBIT of $370M. That compares with $-250M in the prior-year period — up 247.0% year over year. That is below the sector sector average of $2.4T. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, 2190.HK's EBIT is now $370M (was $-250M) — a 247.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Zylox-Tonbridge Medical Technology , Ltd. is outperforming or lagging.
The its sector sector average EBIT is about $2.4T. Zylox-Tonbridge Medical Technology , Ltd. is at $370M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how 2190.HK stacks up against individual peers as well.
Tracking 2190.HK's ebit over time shows whether Zylox-Tonbridge Medical Technology , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $370M That compares with $-250M in the prior-year period — up 247.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this ebit page, Stockcircle has Zylox-Tonbridge Medical Technology , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $370M) with ownership activity and broader fundamentals.